Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Encapsulated Pancreatic Islet Precursor Cells

            Therapeutic Area: Endocrinology Product Name: PEC-Encap

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bain Capital Life Sciences

            Deal Size: $115.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing June 09, 2021

            Details:

            The Company is currently advancing a Phase II clinical study on its product candidate PEC-Encap. PEC-Encap (VC-01) is drug-device combination, where PEC-01 cells are loaded into an Encaptra drug delivery System.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PEC-01 Cell

            Therapeutic Area: Endocrinology Product Name: VC-02

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2021

            Details:

            VC-02 is designed to enable production of both insulin and glucagon to modulate blood glucose, improve time in range, and ameliorate or prevent complications associated with type 1 diabetes. Phase 2 clinical studies to evaluate the safety and efficacy of VC-02 are ongoing.